Distinct expression patterns of the E3 ligase SIAH-1 and its partner Kid/KIF22 in normal tissues and in the breast tumoral processes

Siah proteins are the human members of an highly conserved family of e3 ubiquitin ligases. several data suggest that siah proteins may have a role in tumor suppression and apoptosis. previously,we reported that siah-1 induces the degradation of kid (kif22),a chromokinesin protein implicated in the normal progression of mitosis and meiosis,by the ubiquitin proteasome pathway. in human breast cancer cells stably transfected with siah-1,kid/kif22 protein level was markedly reduced whereas,the kid/kif22 mrna level was increased. this interaction has been further elucidated through analyzing siah and kid/kif22 expression in both paired normal and tumor tissues and cell lines. it was observed that siah-1 protein is widely expressed in different normal tissues,and in cells lines but showing some differences in western blotting profiles. immunofluorescence microscopy shows that the intracellular distribution of siah-1 and kid/kif22 appears to be modified in human tumor tissues compared to normal controls. when mrna expression of siah-1 and kid/kif22 was analyzed by real-time pcr in normal and cancer breast tissues from the same patient,a large variation in the number of mrna copies was detected between the different samples. in most cases,siah-1 mrna is decreased in tumor tissues compared to their normal counterparts. interestingly,in all breast tumor tissues analyzed,variations in the kid/kif22 mrna levels mirrored those seen with siah-1 mrnas. this concerted variation of siah-1 and kid/kif22 messengers suggests the existence of an additional level of control than the previously described protein-protein interaction and protein stability regulation. our observations also underline the need to re-evaluate the results of gene expression obtained by qrt-pcr and relate it to the protein expression and cellular localization when matched normal and tumoral tissues are analyzed. © 2010 bruzzoni-giovanelli et al; licensee biomed central ltd.